Toth Financial Advisory Corp Sells 557 Shares of Amgen Inc. (NASDAQ:AMGN)

Toth Financial Advisory Corp trimmed its position in shares of Amgen Inc. (NASDAQ:AMGN) by 2.1% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 25,562 shares of the medical research company’s stock after selling 557 shares during the quarter. Toth Financial Advisory Corp’s holdings in Amgen were worth $6,662,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of AMGN. Capital Performance Advisors LLP purchased a new position in Amgen during the 3rd quarter worth $25,000. Legacy Investment Solutions LLC purchased a new stake in shares of Amgen during the third quarter worth about $29,000. Hershey Financial Advisers LLC purchased a new stake in shares of Amgen during the second quarter worth about $30,000. Matrix Trust Co acquired a new position in shares of Amgen during the third quarter valued at about $36,000. Finally, Livelsberger Financial Advisory purchased a new position in shares of Amgen in the 3rd quarter valued at approximately $56,000. 76.50% of the stock is currently owned by institutional investors.

Amgen Stock Down 0.9 %

Shares of NASDAQ AMGN opened at $275.42 on Friday. The company has a quick ratio of 0.96, a current ratio of 1.32 and a debt-to-equity ratio of 7.55. Amgen Inc. has a 52-week low of $253.30 and a 52-week high of $346.85. The firm has a market cap of $148.05 billion, a price-to-earnings ratio of 35.27, a price-to-earnings-growth ratio of 2.78 and a beta of 0.56. The company’s 50-day simple moving average is $271.39 and its 200-day simple moving average is $305.99.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Wednesday, October 30th. The medical research company reported $5.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.11 by $0.47. Amgen had a return on equity of 168.35% and a net margin of 13.00%. The firm had revenue of $8.50 billion for the quarter, compared to analyst estimates of $8.50 billion. During the same period in the previous year, the company posted $4.96 earnings per share. The business’s revenue was up 23.2% on a year-over-year basis. Equities analysts predict that Amgen Inc. will post 19.56 EPS for the current fiscal year.

Amgen Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, February 14th will be given a $2.38 dividend. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.46%. This is a boost from Amgen’s previous quarterly dividend of $2.25. The ex-dividend date of this dividend is Friday, February 14th. Amgen’s dividend payout ratio is 115.24%.

Analyst Ratings Changes

Several equities research analysts have recently commented on the stock. UBS Group lowered their price objective on shares of Amgen from $335.00 to $326.00 and set a “neutral” rating for the company in a research note on Thursday, October 31st. Wells Fargo & Company cut their price objective on Amgen from $335.00 to $280.00 and set an “equal weight” rating on the stock in a report on Friday, January 10th. Deutsche Bank Aktiengesellschaft decreased their target price on Amgen from $305.00 to $285.00 in a report on Wednesday, November 27th. Bank of America reiterated an “underperform” rating and issued a $256.00 price target on shares of Amgen in a report on Tuesday, December 10th. Finally, StockNews.com cut shares of Amgen from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, December 18th. Two analysts have rated the stock with a sell rating, twelve have issued a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $314.65.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.